1. Home
  2. ZNTL vs AXR Comparison

ZNTL vs AXR Comparison

Compare ZNTL & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • AXR
  • Stock Information
  • Founded
  • ZNTL 2014
  • AXR 1961
  • Country
  • ZNTL United States
  • AXR United States
  • Employees
  • ZNTL N/A
  • AXR N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • AXR Homebuilding
  • Sector
  • ZNTL Health Care
  • AXR Real Estate
  • Exchange
  • ZNTL Nasdaq
  • AXR Nasdaq
  • Market Cap
  • ZNTL 227.0M
  • AXR 203.2M
  • IPO Year
  • ZNTL 2020
  • AXR N/A
  • Fundamental
  • Price
  • ZNTL $2.25
  • AXR $31.28
  • Analyst Decision
  • ZNTL Buy
  • AXR
  • Analyst Count
  • ZNTL 8
  • AXR 0
  • Target Price
  • ZNTL $10.50
  • AXR N/A
  • AVG Volume (30 Days)
  • ZNTL 1.6M
  • AXR 34.8K
  • Earning Date
  • ZNTL 02-25-2025
  • AXR 03-07-2025
  • Dividend Yield
  • ZNTL N/A
  • AXR N/A
  • EPS Growth
  • ZNTL N/A
  • AXR N/A
  • EPS
  • ZNTL N/A
  • AXR 2.30
  • Revenue
  • ZNTL $40,560,000.00
  • AXR $63,223,000.00
  • Revenue This Year
  • ZNTL N/A
  • AXR N/A
  • Revenue Next Year
  • ZNTL N/A
  • AXR N/A
  • P/E Ratio
  • ZNTL N/A
  • AXR $14.26
  • Revenue Growth
  • ZNTL N/A
  • AXR 54.34
  • 52 Week Low
  • ZNTL $2.16
  • AXR $15.88
  • 52 Week High
  • ZNTL $18.07
  • AXR $39.67
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 32.94
  • AXR 48.60
  • Support Level
  • ZNTL $2.16
  • AXR $27.81
  • Resistance Level
  • ZNTL $2.93
  • AXR $34.00
  • Average True Range (ATR)
  • ZNTL 0.28
  • AXR 1.38
  • MACD
  • ZNTL -0.07
  • AXR 0.30
  • Stochastic Oscillator
  • ZNTL 7.69
  • AXR 56.06

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

Share on Social Networks: